Effect of Hydrogen-rich Water During Tapering on Recovery After Functional Overreaching in Basketball Players
Effect of Hydrogen-rich Water Supplementation During Tapering on Recovery After Functional Overreaching in Competitive Male Basketball Players: A Randomized, Double-blind, Placebo-controlled Paralel-group Trial
The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:
- Does hydrogen-rich water improve autonomic recovery after functional overreaching?
- Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering?
Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:
- Complete a training cycle including normal training, functional overreaching, and tapering.
- Consume hydrogen-rich or placebo water daily during the one-week tapering period.
- Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study consists of an initial screening and entry testing phase, followed by one week of normal training, two weeks of functional overreaching, and one week of tapering. During the functional overreaching period, training load is increased to approximately 120-130% of normal training load to induce accumulated fatigue. During the tapering period, training volume is reduced to approximately 50-60% of normal training volume to support recovery and performance rebound.
The molecular hydrogen is administered only during the tapering period. Participants in the experimental group consume 2.5 L per day of hydrogen-rich water. The total daily dose is divided into 0.5 L in the morning, 1.5 L around training, and 0.5 L in the evening. Participants in the placebo group consume visually matched placebo water according to the same total daily intake and timing schedule. Supplementation adherence is monitored using logs, dose counts, and attendance records. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the placebo group. Randomization is performed using a block scheme and a computer random number generator.
Testing is performed at multiple time points: entry laboratory testing, baseline after normal training, post-functional overreaching, and post-taper. The primary interval for evaluation is the change from post-functional overreaching to post-taper. Statistical analysis is based on a t-test or analysis of variance. Data that not follow a normal distribution are treated using a logarithmic transformation or analyzed using nonparametric tests. The significance level is set at 0.05.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jakub Krejci, PhD
- Correo electrónico: jakub.krejci@upol.cz
Copia de seguridad de contactos de estudio
- Nombre: Jan Kvas
- Número de teléfono: +420774678756
- Correo electrónico: jan.kvas01@upol.cz
Ubicaciones de estudio
-
-
-
Olomouc, Chequia, 77111
- Reclutamiento
- Palacky University, Faculty of Physical Culture
-
Contacto:
- Jan Kvas
- Número de teléfono: +420774678756
- Correo electrónico: jan.kvas01@upol.cz
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Competitive male basketball players.
- Signed informed consent.
- Completion of entry medical and laboratory screening.
Exclusion Criteria:
- Acute injury or infection.
- History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
- Use of medication affecting recovery markers or study results.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Hydrogen-rich water
Hydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period.
|
Hydrogen-rich water with molecular hydrogen concentration >1.0 ppm.
Otros nombres:
|
|
Comparador de placebos: Placebo water
Placebo water administered at a dose of 2.5 L per day during a one-week tapering period.
|
Tap water without molecular hydrogen.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
RMSSD
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.
|
One-week change between post-overreaching and post-taper.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Creatine kinase
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Blood creatine kinase concentration is used as a marker of muscle damage.
|
One-week change between post-overreaching and post-taper.
|
|
High-sensitivity C-reactive protein
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
High-sensitivity C-reactive protein concentration is used as a marker of systemic inflammatory.
|
One-week change between post-overreaching and post-taper.
|
|
Cortisol
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Blood cortisol concentration is used as a marker of physiological stress response.
|
One-week change between post-overreaching and post-taper.
|
|
Testosterone
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Blood testosterone concentration is used as a marker related to anabolic-catabolic balance.
|
One-week change between post-overreaching and post-taper.
|
|
Urea
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Blood urea concentration is used as a marker related to metabolic and protein-turnover stress.
|
One-week change between post-overreaching and post-taper.
|
|
Leukocytes
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Blood leukocyte count is used as a marker of immune-related response to training.
|
One-week change between post-overreaching and post-taper.
|
|
Lymphocytes
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Blood lymphocyte count is used as a marker of immune-related response to training.
|
One-week change between post-overreaching and post-taper.
|
|
Neutrophils
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Blood lymphocyte count is used as a marker of imflammatory response to training.
|
One-week change between post-overreaching and post-taper.
|
|
Reactive strength index
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Reactive strength index is used as an marker of neuromuscular function of the lower limbs and is measured using a drop jump.
|
One-week change between post-overreaching and post-taper.
|
|
Hangrip test
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Handgrip test is used as a marker of forearm muscle strength and is measured using a dynamometer.
|
One-week change between post-overreaching and post-taper.
|
|
20-m sprint
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
20-m sprint test is used to assess linear speed.
|
One-week change between post-overreaching and post-taper.
|
|
Repeated sprint
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
20 x 15 m repeated sprint test is used to asses repeated sprint ability.
|
One-week change between post-overreaching and post-taper.
|
|
Agility T-test
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Agility T-test is used to assess planned change-of-direction performance.
|
One-week change between post-overreaching and post-taper.
|
|
Basketball jump shot accuracy test
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Basketball jump shot accuracy test is used to assess basketball-specific performance.
|
One-week change between post-overreaching and post-taper.
|
|
Muscle soreness
Periodo de tiempo: One-week change between post-overreaching and post-taper.
|
Muscle soreness is assessed subjectively using a visual analog scale, which is represented by a 100 mm line marked 0 (no pain) and 100 (worst imaginable pain).
|
One-week change between post-overreaching and post-taper.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jan Kvas, Palacky University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- FTK_2026_13
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .